“药创新”综合整理过去一周，创新药行业发生了哪些事儿？礼来达成3笔交易，涉及免疫疾病、肿瘤和减肥药；3款“全球首创”新药在华获批，分别来自默沙东、赛诺菲和恒瑞医药；宜联生物与罗氏再次达成ADC管线交易；GSK宣布乙肝新药III期成功，显著提升功能性治愈率……详情如下：新药获批全球首个肺动脉高压对因疗法在华获批1月5日，默沙东宣布，全球首个且目前唯一突破性疗法激活素信号传导抑制剂（ASI）欣瑞来（...
Source Link“药创新”综合整理过去一周，创新药行业发生了哪些事儿？礼来达成3笔交易，涉及免疫疾病、肿瘤和减肥药；3款“全球首创”新药在华获批，分别来自默沙东、赛诺菲和恒瑞医药；宜联生物与罗氏再次达成ADC管线交易；GSK宣布乙肝新药III期成功，显著提升功能性治愈率……详情如下：新药获批全球首个肺动脉高压对因疗法在华获批1月5日，默沙东宣布，全球首个且目前唯一突破性疗法激活素信号传导抑制剂（ASI）欣瑞来（...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.